Stem cell technology for neurodegenerative diseases
Identifieur interne : 000644 ( Main/Corpus ); précédent : 000643; suivant : 000645Stem cell technology for neurodegenerative diseases
Auteurs : J. Simon Lunn ; Stacey A. Sakowski ; Junguk Hur ; Eva L. FeldmanSource :
- Annals of Neurology [ 0364-5134 ] ; 2011-09.
Abstract
Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases. Ann Neurol 2011;70: 353–361.
Url:
DOI: 10.1002/ana.22487
Links to Exploration step
ISTEX:8F03EAF9D8C28C217B1EAD7DF92025F16781061DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stem cell technology for neurodegenerative diseases</title><author><name sortKey="Lunn, J Simon" sort="Lunn, J Simon" uniqKey="Lunn J" first="J. Simon" last="Lunn">J. Simon Lunn</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author><author><name sortKey="Sakowski, Stacey A" sort="Sakowski, Stacey A" uniqKey="Sakowski S" first="Stacey A." last="Sakowski">Stacey A. Sakowski</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author><author><name sortKey="Hur, Junguk" sort="Hur, Junguk" uniqKey="Hur J" first="Junguk" last="Hur">Junguk Hur</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author><author><name sortKey="Feldman, Eva L" sort="Feldman, Eva L" uniqKey="Feldman E" first="Eva L." last="Feldman">Eva L. Feldman</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8F03EAF9D8C28C217B1EAD7DF92025F16781061D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/ana.22487</idno><idno type="url">https://api.istex.fr/document/8F03EAF9D8C28C217B1EAD7DF92025F16781061D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000644</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Stem cell technology for neurodegenerative diseases</title><author><name sortKey="Lunn, J Simon" sort="Lunn, J Simon" uniqKey="Lunn J" first="J. Simon" last="Lunn">J. Simon Lunn</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author><author><name sortKey="Sakowski, Stacey A" sort="Sakowski, Stacey A" uniqKey="Sakowski S" first="Stacey A." last="Sakowski">Stacey A. Sakowski</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author><author><name sortKey="Hur, Junguk" sort="Hur, Junguk" uniqKey="Hur J" first="Junguk" last="Hur">Junguk Hur</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author><author><name sortKey="Feldman, Eva L" sort="Feldman, Eva L" uniqKey="Feldman E" first="Eva L." last="Feldman">Eva L. Feldman</name><affiliation><mods:affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-09">2011-09</date><biblScope unit="volume">70</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="353">353</biblScope><biblScope unit="page" to="361">361</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">8F03EAF9D8C28C217B1EAD7DF92025F16781061D</idno><idno type="DOI">10.1002/ana.22487</idno><idno type="ArticleID">ANA22487</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases. Ann Neurol 2011;70: 353–361.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>J. Simon Lunn PhD</name><affiliations><json:string>Department of Neurology, University of Michigan, Ann Arbor, MI</json:string></affiliations></json:item><json:item><name>Stacey A. Sakowski PhD</name><affiliations><json:string>Department of Neurology, University of Michigan, Ann Arbor, MI</json:string></affiliations></json:item><json:item><name>Junguk Hur PhD</name><affiliations><json:string>Department of Neurology, University of Michigan, Ann Arbor, MI</json:string></affiliations></json:item><json:item><name>Eva L. Feldman MD, PhD</name><affiliations><json:string>Department of Neurology, University of Michigan, Ann Arbor, MI</json:string></affiliations></json:item></author><articleId><json:string>ANA22487</json:string></articleId><language><json:string>eng</json:string></language><abstract>Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases. Ann Neurol 2011;70: 353–361.</abstract><qualityIndicators><score>7.492</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 801 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1182</abstractCharCount><pdfWordCount>5613</pdfWordCount><pdfCharCount>37440</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>166</abstractWordCount></qualityIndicators><title>Stem cell technology for neurodegenerative diseases</title><genre><json:string>article</json:string></genre><host><volume>70</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>9</total><last>361</last><first>353</first></pages><issn><json:string>0364-5134</json:string></issn><issue>3</issue><subject><json:item><value>Neurological Progress</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/ana.22487</json:string></doi><id>8F03EAF9D8C28C217B1EAD7DF92025F16781061D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8F03EAF9D8C28C217B1EAD7DF92025F16781061D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8F03EAF9D8C28C217B1EAD7DF92025F16781061D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8F03EAF9D8C28C217B1EAD7DF92025F16781061D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Stem cell technology for neurodegenerative diseases</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Stem cell technology for neurodegenerative diseases</title><author><persName><forename type="first">J. Simon</forename><surname>Lunn</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation></author><author><persName><forename type="first">Stacey A.</forename><surname>Sakowski</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation></author><author><persName><forename type="first">Junguk</forename><surname>Hur</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation></author><author><persName><forename type="first">Eva L.</forename><surname>Feldman</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Michigan, 109 Zina Pitcher Place, 5017 BSRB, Ann Arbor, MI 48109‐2200</p></note><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-09"></date><biblScope unit="volume">70</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="353">353</biblScope><biblScope unit="page" to="361">361</biblScope></imprint></monogr><idno type="istex">8F03EAF9D8C28C217B1EAD7DF92025F16781061D</idno><idno type="DOI">10.1002/ana.22487</idno><idno type="ArticleID">ANA22487</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases. Ann Neurol 2011;70: 353–361.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Neurological Progress</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-12-02">Received</change><change when="2011-05-16">Registration</change><change when="2011-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8F03EAF9D8C28C217B1EAD7DF92025F16781061D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/ana.v70.3</doi><numberingGroup><numbering type="journalVolume" number="70">70</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2011-09">September 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.22487</doi><idGroup><id type="unit" value="ANA22487"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Neurological Progress</title><title type="tocHeading1">Neurological Progress</title></titleGroup><copyright ownership="publisher">Copyright © 2011 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="2010-12-02"></event><event type="manuscriptRevised" date="2011-05-10"></event><event type="manuscriptAccepted" date="2011-05-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.9.3 mode:FullText" date="2011-09-08"></event><event type="publishedOnlineAccepted" date="2011-05-20"></event><event type="firstOnline" date="2011-09-08"></event><event type="publishedOnlineFinalForm" date="2011-09-08"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">353</numbering><numbering type="pageLast">361</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Michigan, 109 Zina Pitcher Place, 5017 BSRB, Ann Arbor, MI 48109‐2200</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA22487.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="81"></count><count type="wordTotal" number="6968"></count></countGroup><titleGroup><title type="main" xml:lang="en">Stem cell technology for neurodegenerative diseases</title><title type="short" xml:lang="en">Stem Cells</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J. Simon</givenNames><familyName>Lunn</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Stacey A.</givenNames><familyName>Sakowski</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Junguk</givenNames><familyName>Hur</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Eva L.</givenNames><familyName>Feldman</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>efeldman@umich.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases. Ann Neurol 2011;70: 353–361.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Stem cell technology for neurodegenerative diseases</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Stem Cells</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Stem cell technology for neurodegenerative diseases</title></titleInfo><name type="personal"><namePart type="given">J. Simon</namePart><namePart type="family">Lunn</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stacey A.</namePart><namePart type="family">Sakowski</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Junguk</namePart><namePart type="family">Hur</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eva L.</namePart><namePart type="family">Feldman</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI</affiliation><description>Correspondence: Department of Neurology, University of Michigan, 109 Zina Pitcher Place, 5017 BSRB, Ann Arbor, MI 48109‐2200</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-09</dateIssued><dateCaptured encoding="w3cdtf">2010-12-02</dateCaptured><dateValid encoding="w3cdtf">2011-05-16</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">1</extent><extent unit="references">81</extent><extent unit="words">6968</extent></physicalDescription><abstract lang="en">Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases. Ann Neurol 2011;70: 353–361.</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Neurological Progress</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>353</start><end>361</end><total>9</total></extent></part></relatedItem><identifier type="istex">8F03EAF9D8C28C217B1EAD7DF92025F16781061D</identifier><identifier type="DOI">10.1002/ana.22487</identifier><identifier type="ArticleID">ANA22487</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000644 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000644 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:8F03EAF9D8C28C217B1EAD7DF92025F16781061D
|texte= Stem cell technology for neurodegenerative diseases
}}
| This area was generated with Dilib version V0.6.23. |  |